RWA Wealth Partners LLC Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN

RWA Wealth Partners LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,604 shares of the biopharmaceutical company’s stock after selling 994 shares during the period. RWA Wealth Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $3,713,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in REGN. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Traub Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $38,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 35 shares during the last quarter. Finally, Berbice Capital Management LLC grew its stake in Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approved Dupixent for allergic fungal rhinosinusitis (AFRS) in patients aged 6+, marking the drug’s ninth U.S. indication and addressing a hard-to-treat sinus disease; approval is supported by Phase 3 data showing symptom reduction and lower need for steroids or repeat surgery, boosting Dupixent’s long-term revenue potential. GlobeNewswire: Dupixent approved for AFRS
• Positive Sentiment: Regeneron and Sanofi announced the same FDA approval in commercial/press coverage highlighting strong Phase 3 data and broader market adoption potential for Dupixent across sino-nasal and type 2 inflammatory diseases. Yahoo: Dupixent AFRS coverage
• Positive Sentiment: The FDA accepted Regeneron’s BLA for garetosmab under Priority Review for fibrodysplasia ossificans progressiva (FOP), accelerating the regulatory timeline for a potential new orphan indication and adding near-term pipeline value if approved. Yahoo: FDA accepts garetosmab BLA
• Positive Sentiment: Analyst and media bullish takes (e.g., The Motley Fool) highlight Regeneron’s product depth, manufacturing capabilities and combined commercial strength with Sanofi as reasons the stock could outperform long-term — supportive commentary that can sustain investor interest after the approval news. Fool: Reasons REGN could outperform
• Neutral Sentiment: Market commentary is flagging short-term price cooling and a valuation reassessment despite recent gains; investors are revisiting multiples and growth assumptions after mixed short-term returns. Yahoo: Valuation assessment
• Neutral Sentiment: Recent MarketBeat coverage notes a modest dividend increase and a range of analyst target revisions — supportive but incremental to valuation — with consensus still in the moderate-buy area. MarketBeat: Analyst notes & dividend
• Negative Sentiment: Regeneron director Huda Zoghbi sold 1,638 shares (~49% reduction of her holding) in a disclosed transaction; while insider sales are common and may be for personal reasons, large disclosed sales can create short-term selling pressure or raise governance questions for some investors. American Banking News: Insider sale

Analysts Set New Price Targets

Several analysts have commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Cantor Fitzgerald upped their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ REGN opened at $784.28 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The business’s 50 day moving average is $770.88 and its two-hundred day moving average is $678.50. The stock has a market capitalization of $82.91 billion, a P/E ratio of 18.87, a PEG ratio of 2.07 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the company earned $12.07 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Insider Activity

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 5,274 shares of company stock worth $4,142,738. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.